Guidelines for Complications of Cancer Treatment Vol VIII Part B

More documents

Recommendations

Info

4. Griffin AM, Parsons JA, Davis AM, et al. Uncementedtumor endoprostheses at the knee: root causes of failure.Clin Orthop Relat Res 2005; 438:71–79.5. Agarwal M, Anchan C, Shah M, et al. Limb salvagesurgery for osteosarcoma: effective low-cost treatment.Clin Orthop Relat Res 2007; 459:82–91.6. Serhan H, Slivka M, Albert T, Kwak SD. Is galvaniccorrosion between titanium alloy and stainless steelspinal implants a clinical concern? Spine J 2004; 4:379–387.7. Cannon, S. R. Massive Prostheses for Malignant BoneTumours of the Limbs. J Bone Joint Surg 1997; 79B:497-5068. Mittermayer F, Windhager F, Dominkus M, et al.Revision of the Kotz type of tumour endoprosthesis forthe lower limb. J Bone Joint Surg 2002;84B:401-4069. Capanna R, Ruggeri P, Decristofaro R, et al.Complications, their treatment and outcome in 257cementless megaprostheses. In: Brown KLB, ed.Complications of limb salvage: prevention, managementand outcome. Montreal, ISOLS, 1991, p147-150.10. Taylor S, Perry J, Adler J, et al. The telemetry of forcesin vivo developed in massive orthopaedic implants: thefirst 18 months, results from walking. In: Tan SK, ed.Limb salvage: current trends. Singapore, ISOLS,1993:560.11. Eckardt JJ, Yang RS, Ward WG, et al. Endoprostheticreconstruction for malignant bone tumors andnontumorous conditions of bone. In Stauffer RN(Ed):Advances in Operative Orthopaedics, 1995; vol.3, pp.61-83.12. Peabody TD, Eckardt JJ: Complications ofendoprosthetic reconstruction. In Simon MA and103
Springfield D (Eds), Surgery for bone and soft tissuetumors, Chap. 35, p467-479. Lippincott-RavenPublisher, Philadelphia, 998.13. Hsu RW, Sim FH, Chao EY. Reoperation results aftersegmental prosthetic replacement of bone and joint forlimb salvage. J Arthroplasty. 1999; 14:519-526.14. Ham SJ, Schraffordt Koops H, Veth RP, et al..Limbsalvage surgery for primary bone sarcoma of the lowerextremities: long-term consequences of endoprostheticreconstructions. Ann Surg Oncol 1998; 5:423-436.15. Schindler OS, Cannon SR, Briggs TW, et al. Stanmorecustom-made extendible distal femoral replacements.Clinical experience in children with primary malignantbone tumours. J Bone Joint Surg 1997; 79B:927-937.16. Ward WG, Yang RS, Eckardt JJ. Endoprosthetic bonereconstruction following malignant tumor resection inskeletally immature patients. Orthop Clin N Am 1996;27:493-502.17. Mittermayer F, Krepler P, Dominkus M, et al. Long-termfollowup of uncemented tumor endoprostheses for thelower extremity. Clin Orthop 2001; 388:167-177.18. Safran MR, Kody MH, Namba RS, et al. . 151endoprosthetic reconstructions for patients with primarytumors involving bone. Contemp Orthop 1994; 29:15-25.19. Scales JT, Wright KWJ. Major bone and jointreplacement using custom implants. In: Chao EYS, IvinsJC, eds. Tumor prostheses for bone and jointreconstruction: the design and application. New York:Thieme-Stratton Inc, Georg Thieme Verlag,1983,149-168.104
Page 1 and 2:
Guidelines forComplications ofCance
Page 3:
Dedicated toAll our patients atThe
Page 6 and 7:
Section IIHead & Neck 151Complicati
Page 8 and 9:
PrefaceTreatment of cancer by vario
Page 10:
Section — IGeneralContributorsDr.
Page 13 and 14:
6. Complications after breast recon
Page 15 and 16:
promises to reduce this risk of ser
Page 17 and 18:
preceded by increased sensory hyper
Page 19 and 20:
had significant lymphoedema. The fa
Page 21 and 22:
2. Smoking as a risk factor for wou
Page 23 and 24:
4. Preoperative core needle biopsy
Page 25 and 26:
eduction mammoplasty, and axillary-
Page 27 and 28:
postoperative wound infection follo
Page 29 and 30:
ablative surgical treatment for car
Page 31 and 32:
postoperative seroma formation usin
Page 33 and 34:
dressing consisted of a circumferen
Page 35 and 36:
mastectomies with axillary node cle
Page 37 and 38:
mastectomy for breast cancer. Early
Page 39 and 40:
monitored for the development of po
Page 41 and 42:
modality, and tumor stage distribut
Page 43 and 44:
26. Pain and other symptoms during
Page 45 and 46:
28. Coping, catastrophizing and chr
Page 47 and 48:
surgical technique at the time of m
Page 49 and 50:
0.001), 0.315 cm +/- 1.27 at the an
Page 51 and 52:
or heat and superficial incision is
Page 53 and 54:
RecommendationsA. Preparation of th
Page 55 and 56:
3. Mangram AJ, Horan TC, Pearson ML
Page 57 and 58:
Mild hypothermia increases blood lo
Page 59 and 60:
Perioperative Normothermia to Reduc
Page 61 and 62: Priorities: Restoration of circulat
Page 63 and 64: than 1.5 times control values but f
Page 65 and 66: outcomes that may result from the u
Page 67 and 68: Preoperative Preparation of the Pat
Page 69 and 70: patients, or other patients who may
Page 71 and 72: Obstruction can occur at the level
Page 74 and 75: c. Administer face mask preoxygenat
Page 76 and 77: 5. The use of exhaled carbon dioxid
Page 78 and 79: disorder) may occur after an episod
Page 80 and 81: undergoing general anesthesia, eith
Page 82 and 83: anesthesia awareness occurred in ea
Page 84 and 85: The current guidelines are actually
Page 86 and 87: o S - Strong Recommendation -Commit
Page 88 and 89: oSource control ASAP after successf
Page 90 and 91: oooWean steroids once vasopressors
Page 92 and 93: Mechanical ventilation of sepsis-in
Page 94 and 95: o CVVH offers easier management inh
Page 96 and 97: critically ill patient that are con
Page 98 and 99: Rivers E, Nguyen B, Havstad S, et a
Page 100 and 101: in survival of 7.6%. By the second
Page 102 and 103: parameters (gastric mucosal Pco2, s
Page 104 and 105: syndrome. We therefore conducted a
Page 106 and 107: Complications After Limb SalvageSur
Page 108 and 109: local tumor and to preserve as much
Page 110 and 111: femoral head to the center of the k
Page 114 and 115: 20. Roberts P, Chan D, Grimer RJ, e
Page 116 and 117: An infection can have disastrous co
Page 118 and 119: and facilitating reimplantation sur
Page 120 and 121: features of a two-stage revision is
Page 122 and 123: patients had an amputation. Two oth
Page 124 and 125: its main role is confined to ruling
Page 126 and 127: 2. Capanna R, Morris HG, Campanacci
Page 128 and 129: 21. Wilson MG, Kelley K, Thornhill
Page 130 and 131: 39. Love C, Marwin SE, Tomas MB, Kr
Page 132 and 133: 5. A systematic review of 25 RCT’
Page 134 and 135: (cefazolin or cefuroxime) or penici
Page 136 and 137: should be based on the isolates fro
Page 138 and 139: such as concomitant use of prophyla
Page 140 and 141: Surgical techniqueAdherence to meti
Page 142 and 143: 2. Another small prospective random
Page 144 and 145: Antibiotic prophylaxis for dental a
Page 146 and 147: Antimicrobial Prophylaxis in Orthop
Page 148 and 149: 35. Tai CC, Nirvani AA, Holmes A, e
Page 150 and 151: 53. Parker MJ, Roberts C. Closed su
Page 152 and 153: Vessel Related Issues in Sarcoma:Ev
Page 154 and 155: sequences may be of value. They cau
Page 156 and 157: an excellent alternative to amputat
Page 158: 5. Hünerbein M, Hohenberger P, Str
Page 162 and 163:
Oral IncompetenceOral competence is
Page 164 and 165:
flap is insensate and has no motor
Page 166 and 167:
16. R. Song, Y. Gao, Y. Song, Y. Yu
Page 168 and 169:
The incidence is usually lower afte
Page 170 and 171:
Late fibrotic phase: Attempted tiss
Page 172 and 173:
Ref: A Lyons, N Ghazali/ British J
Page 174 and 175:
17. Store G, Boysen M. Mandibular o
Page 176 and 177:
amino acids, proteins and traces of
Page 178 and 179:
RTOG, EORTC and CTCAE, version 3 fo
Page 180 and 181:
difference in the disease related p
Page 182 and 183:
References1. Bourhis J, Rosine D. R
Page 184 and 185:
with head and neck cancer. N Engl J
Page 186 and 187:
MucositisMucositis is an inflammato
Page 188 and 189:
Type of cancer: high risk for mucos
Page 190 and 191:
Oral care protocol1. Brush all toot
Page 192 and 193:
3. El-Sayed S, Nabid A, ShelleyW, e
Page 194 and 195:
1) Recipient site problems- The maj
Page 196 and 197:
estoration of vascular flow to tiss
Page 198 and 199:
General Complications- Deep vein th
Page 200 and 201:
Nerve Injuries(Recurrent and Superi
Page 202 and 203:
paramedian position, it will result
Page 204 and 205:
along with its variations, and a me
Page 206 and 207:
anatomy as related to surgery of th
Page 208 and 209:
Risk factorsCentral compartment (Le
Page 210 and 211:
Goal - To raise serum calcium level
Page 212 and 213:
Pharyngocutaneous Fistula (PC Fistu
Page 214 and 215:
Based on our institutional practice
Page 216 and 217:
fistula: The Memorial University ex
Page 218 and 219:
Risk factors (LOE-5)Patient factors
Page 220 and 221:
oCircumferencial excision and inser
Page 222 and 223:
y trauma or tumor, exposing the und
Page 224 and 225:
Arytenoid cartilage is reported to
Page 226 and 227:
Filntisis, G.A., et al. “Laryngea
Page 228 and 229:
As high as 52% patients are detecte
Page 230 and 231:
ManagementPostural exercisesDisorde
Page 232 and 233:
References1) Objective assessment o
Page 234 and 235:
Diagnosis Average time to hypothyro
Page 236 and 237:
Management of Facial Nerve InjuryIn
Page 238 and 239:
2. Interposition or cable graft (to
Page 240 and 241:
Prevention of corneal exposure Tars
Page 242 and 243:
flushing) and localized sweating (g
Page 244 and 245:
Other options :1. Intracutaneous in
Page 246 and 247:
Shoulder Dysfunction or PainfulShou
Page 248 and 249:
EMG studies on scapulo-humeral and
Page 250 and 251:
Chyle Fistula after Neck Dissection
Page 252 and 253:
Rationale:LCTs, which constitute 70
Page 254 and 255:
CSF Leak after Craniofacial Resecti
Page 256 and 257:
to the muscle to recreate the orbit
Page 258 and 259:
Conservative treatmentIt is logical
Page 260 and 261:
Complications Associated with use o
Page 262 and 263:
Following is the example of hematol
Page 264 and 265:
ooooooo direct interaction with the
Page 266 and 267:
ooooointravenously over 15 minutes
Page 268 and 269:
in most of the patients. The common
Page 270:
Section — IIIRadiotherapyContribu
Page 273 and 274:
nodes are involved or suspected to
Page 275 and 276:
function. In general, with conventi
Page 277 and 278:
like ultrasonography, CT scan, endo
Page 279 and 280:
catheter passed through the anus in
Page 281 and 282:
Acute symptoms usually subside seve
Page 283 and 284:
granulocytopenia, thrombocytopenia
Page 285 and 286:
adiation therapy), IMRT (intensity-
Page 287 and 288:
patients who have received radical
Page 289 and 290:
ate expected in the standard popula
Page 292 and 293:
adjusting for competing causes of d
Page 294 and 295:
therapy (3D-CRT) and intensity modu
Page 296 and 297:
attributed to use of cisplatin base
Page 298 and 299:
Conclusion:Incidence of SMN is incr
Page 300 and 301:
11. Travis LB, Fossa SD, Schonfeld
Page 302 and 303:
adiation-related solid SMNs will in
Page 304 and 305:
0.71, p
Page 306 and 307:
5.65%) within 45 years after a CNS
Page 308 and 309:
adiation damage though supporting v
Page 310 and 311:
without calcification. Inflammation
Page 312 and 313:
patients treated using the original
Page 314 and 315:
incidence of valvular thickening at
Page 316 and 317:
12. Hancock S, Hoppe R. Long-term c
Page 318 and 319:
syndrome and bronchiolitis oblitera
Page 320 and 321:
Darby SC, McGale P, Taylor CW, Peto
Page 322 and 323:
undertaken, based on individual pat
Page 324 and 325:
Pathophysiological Aspects:The func
Page 326 and 327:
Symptoms: Symptoms related to pulmo
Page 328 and 329:
Prevention of Pneumonitis and Lung
Page 330 and 331:
genotyping analysis of single nucle
Page 332 and 333:
Registry of Patients. We computed I
Page 334 and 335:
eceived elective nodal irradiation
Page 336 and 337:
Int J Radiat Oncol Biol Phys. 1995
Page 338 and 339:
worsening during the treatment shou
Page 340 and 341:
Differential Diagnosis: This sign i
Page 342 and 343:
Dose Incidence Comments Author>30 G
Page 344 and 345:
PET scan findings have been describ
Page 346 and 347:
3. Pallis CA, Louis S, Morgan RL.:
Page 348 and 349:
24. Abbatucci JS, Delozier T, Quint
Page 350 and 351:
and summarized into specific recomm
Page 352 and 353:
adequate. With the increasing use o
Page 354 and 355:
Complications are mainly described
Page 356 and 357:
IQ decline is associated with sever
Page 358 and 359:
activity’ of a person, essentiall
Page 360 and 361:
development after brain tumor thera
Page 362 and 363:
Highest relative risk of second can
Page 364 and 365:
Suggested Reading:A) Neuropsycholog
Page 366 and 367:
aseline. Male sex, longer symptomat
Page 368 and 369:
number of patients. Cognition was p
Page 370 and 371:
16 years, the corresponding value w
Page 372 and 373:
15 of 20 (75%) subjects, endocrine
Page 374 and 375:
OBJECTIVE: To assess cerebrovascula
Page 376 and 377:
hypometabolism. Of the 17 patients
Page 378:
10-20 months, with an average of 18
Page 382 and 383:
Febrile NeutropeniaNeutropenia is w
Page 384 and 385:
Approach to initial antibiotic use
Page 386 and 387:
Known colonization with Penicillin/
Page 388 and 389:
DocumentedinfectionsSuggesteddurati
Page 390 and 391:
Zygomycosis and other mold infectio
Page 392 and 393:
Overall risk Examples Febrile neutr
Page 394 and 395:
Broad spectrum DOSE Spectrum Commen
Page 396 and 397:
Page 398 and 399:
Page 400 and 401:
Role of G-CSF-Primary Prophylaxis:R
Page 402 and 403:
Chemotherapy Induced Nausea andVomi
Page 404 and 405:
Level I Level II Level III Level IV
Page 406 and 407:
Types & doses of AntiemeticsDrug &
Page 408 and 409:
supported by a meta-analysis, which
Page 410 and 411:
and follow-up after treatment for n
Page 412 and 413:
day 1; aprepitant and dexamethasone
Page 414 and 415:
2-3: APR 80 mg every day) or a cont
Page 416 and 417:
Late Effects in Childhood CancerSur
Page 418 and 419:
to increase their awareness about l
Page 420 and 421:
Contd...Score2BStatement of consens
Page 422 and 423:
6 Kurkure PA, Achrekar S, Uparkar U
Page 424 and 425:
nonirradiated group did not differ
Page 426 and 427:
Gaslini Children’s Research Hospi
Page 428 and 429:
Our ACT model has 3 basic facets; p
Page 430 and 431:
The relative risk of developing TLS
Page 432 and 433:
the excretion of uric acid and phos
Page 434 and 435:
hyperuricemia (> 7.5 mg/dL), treatm
Page 436 and 437:
hydration, and the administration o
Page 438 and 439:
which the different drugs are admin
Page 440 and 441:
Table 2. Cairo-Bishop clinical Tumo
Page 442 and 443:
Table 4 Patient Stratification by R
Page 444 and 445:
Table 6 Management of Electrolyte A
Page 446 and 447:
of TLS and improve the management o
Page 448 and 449:
4. Efficacy and safety of rasburica
Page 450 and 451:
Pulmonary Toxicity of Antineoplasti
Page 452 and 453:
Though there are many chemotherapeu
Page 454 and 455:
corticosteroids with variable respo
Page 456 and 457:
Nephrotoxicity ofChemotherapeutic D
Page 458 and 459:
associated with use of carbopltin c
Page 460 and 461:
Table 2 Chemotherapeutics Requiring
Page 462 and 463:
against ifosfamide nephrotoxicity.
Page 464 and 465:
The incidence of mucositis involvin
Page 466 and 467:
7. Obesity - Probably due to over d
Page 468 and 469:
conditioning treatment and for 3 da
Page 470 and 471:
References and Recommended Readings
Page 472 and 473:
metabolism for activity, cyclophosp
Page 474 and 475:
delays excretion and eventually res
Page 476 and 477:
Combination Chemotherapy:Combinatio
Page 478 and 479:
Vincristine: No dose reduction if b
Page 480 and 481:
19. Slichenmyer WJ, Rowinsky EK, Gr
Page 482 and 483:
AlopeciaCommon drugs causing alopec
Page 484 and 485:
dependent, occurring from 8 days to
Page 486 and 487:
Cancer Induced Anemia (CIA)Introduc
Page 488 and 489:
system. There is an upregulation of
Page 490 and 491:
time may represent increasing anemi
Page 492 and 493:
(rHuEPO) whiles the other received
Page 494 and 495:
Table 3. Improvements in Hemoglobin
Page 496 and 497:
2. Groopman JE, Itri LM. Chemothera
Page 498 and 499:
epoetin alfa versus oral iron or no
Page 500 and 501:
NOTES
show all

Guidelines for Complications of Cancer Treatment Vol VIII Part B

Create successful ePaper yourself

Delete template?

Save as template?